Last updated: July 31, 2026
Sodium iodide I-131 is a mature therapeutic radiopharmaceutical used mainly for hyperthyroidism and differentiated thyroid cancer. Its clinical value is established, but its commercial growth is constrained by generic availability, declining use in some low-risk thyroid-cancer patients, radiation-safety requirements, and competition from surgery, antithyroid drugs, external-beam radiotherapy, and newer targeted radioligand therapies. The product has limited conventional patent value. The main barriers to competition are radioactive-isotope supply, manufacturing authorization, pharmacy infrastructure, quality systems, and hospital logistics.
What is sodium iodide I-131 used for?
Sodium iodide I-131 delivers beta radiation to thyroid tissue after selective uptake through the sodium-iodide symporter. Gamma emissions permit imaging and dosimetry, while beta emissions produce the therapeutic effect.
| Clinical use |
Commercial role |
Evidence position |
| Graves' disease |
Established definitive treatment |
Guideline-supported |
| Toxic multinodular goiter |
Established treatment |
Guideline-supported |
| Toxic adenoma |
Established treatment |
Guideline-supported |
| Remnant ablation after thyroidectomy |
Selective use in differentiated thyroid cancer |
Risk-adapted |
| Treatment of iodine-avid metastatic thyroid cancer |
Established systemic treatment |
Standard for eligible patients |
| Diagnostic thyroid imaging |
Historically important, now often replaced by I-123 or other imaging methods |
Declining relative role |
The principal products are oral capsules and oral solutions. Hospitals and nuclear pharmacies generally procure sodium iodide I-131 by activity, measured in millicuries or gigabecquerels, rather than by conventional tablet volume.
The drug is not a conventional small-molecule pharmaceutical in commercial terms. Its active therapeutic element is the radioactive isotope iodine-131, which has an approximately eight-day physical half-life. Product value therefore depends on production scheduling, transport speed, calibration, and administration before radioactive decay reduces usable activity.
What is the FDA regulatory status of sodium iodide I-131?
Sodium iodide I-131 is an FDA-approved prescription radiopharmaceutical. FDA labeling covers treatment of hyperthyroidism and thyroid carcinoma, including thyroid tissue and metastases that retain iodine uptake, subject to the specific product label and clinical indication.[1]
The product is regulated through several overlapping systems:
- FDA approval and drug-quality requirements.
- Current good manufacturing practice requirements.
- Radioactive-material licensing by the Nuclear Regulatory Commission or an Agreement State.
- State pharmacy and radiation-control rules.
- Transportation requirements for radioactive materials.
- Institutional nuclear-medicine and radiation-safety controls.
Sodium iodide I-131 does not have the regulatory profile of a newly developed oncology drug. The active ingredient has been used clinically for decades, and the principal regulatory risk is manufacturing continuity, product quality, and radioactive-material handling rather than proof of a new mechanism.
What is the Orange Book status of sodium iodide I-131?
The Orange Book is less commercially informative for sodium iodide I-131 than for recently approved branded drugs. The product is supplied by multiple radiopharmaceutical manufacturers and nuclear pharmacies, and its commercial competition is primarily based on availability, activity, geography, reliability, and institutional contracts.
There is no widely recognized active composition-of-matter patent that provides durable exclusivity over sodium iodide I-131 itself. Any relevant listing would need to be assessed at the specific product, NDA, formulation, and manufacturer level. In practical terms, the commercial market is not protected by a single dominant patent estate comparable to those surrounding high-value oncology biologics.
What clinical trials are evaluating sodium iodide I-131?
Most sodium iodide I-131 research is post-approval clinical work rather than conventional registration-stage development. Trial activity generally addresses patient selection, administered activity, response assessment, preparation, dosimetry, and combination treatment.
Current clinical research themes
| Research area |
Typical objective |
Commercial effect |
| Radioiodine-refractory disease |
Identify patients unlikely to respond before treatment |
May reduce inappropriate use |
| Redifferentiation therapy |
Restore iodine uptake using kinase inhibitors or epigenetic agents |
Could expand eligible patient population |
| Dosimetry |
Individualize administered activity |
May improve safety and resource use |
| Low-dose ablation |
Compare lower activity with traditional treatment |
Could reduce inpatient capacity needs |
| Thyroid-stimulating hormone preparation |
Compare recombinant TSH with hormone withdrawal |
Supports outpatient convenience |
| Pediatric thyroid cancer |
Optimize activity by weight, body surface area, or dosimetry |
Maintains specialized demand |
| Combination therapy |
Pair I-131 with targeted agents |
Could increase use in selected patients |
| Long-term safety |
Evaluate second malignancies, salivary injury, fertility, and marrow effects |
Influences treatment selection |
ClinicalTrials.gov identifies studies involving radioiodine treatment, differentiated thyroid cancer, Graves' disease, dosimetry, and redifferentiation. The majority are investigator-led or academic rather than sponsor-led trials designed to support a new sodium iodide I-131 product approval.[2]
The most commercially relevant development path is not a new I-131 molecule. It is the use of molecularly targeted drugs to restore sodium-iodide symporter expression in patients whose tumors have become radioiodine-refractory. Such programs could create additional demand for I-131, but they also shift value toward the combination partner.
When does sodium iodide I-131 lose exclusivity?
Sodium iodide I-131 does not face a conventional single-date patent cliff comparable to a branded oral oncology drug. Its core active ingredient is longstanding, and multiple suppliers operate in the market.
| Exclusivity category |
Current commercial position |
| Composition-of-matter patent |
No meaningful current exclusivity over sodium iodide I-131 itself |
| Basic therapeutic use |
Long-established and generally unprotected |
| Capsule or solution formulation |
Potentially protectable in theory, but limited practical differentiation |
| Manufacturing process |
May be protected as know-how or facility-specific process information |
| FDA new-drug exclusivity |
Not the primary commercial barrier |
| Supplier contract protection |
Often more relevant than patent protection |
| Geographic supply rights |
Important where one nuclear pharmacy or reactor network dominates |
Patent expiration is therefore not the principal generic-entry event. Entry depends on whether a manufacturer can obtain the necessary approvals, source iodine-131, establish validated production and testing, meet radioactive-material rules, and deliver product within the usable activity window.
What patents protect sodium iodide I-131?
The active drug itself has little defensible patent scope. Potential patent categories include:
- Modified capsule compositions or packaging.
- Stabilized oral solutions.
- Automated dispensing or dose-calibration systems.
- Radiopharmaceutical production methods.
- Patient-specific dosimetry methods.
- Combination regimens that restore iodine uptake.
- Imaging and treatment workflows.
- Specialized delivery systems for targeted iodine therapy.
The strongest commercially relevant intellectual property is more likely to surround combination therapy or treatment selection than sodium iodide I-131. For example, a kinase inhibitor used to restore radioiodine uptake could have method-of-use patents even though I-131 itself is unpatented.
How strong is the patent estate for sodium iodide I-131?
The patent estate is weak for the active ingredient and moderate for selected ancillary technologies.
| Asset |
Patent strength |
Main reason |
| Sodium iodide I-131 active ingredient |
Low |
Old, established substance |
| Standard oral capsule |
Low |
Limited differentiation |
| Standard oral solution |
Low to moderate |
Formulation claims may be narrow |
| Automated nuclear-pharmacy dispensing |
Moderate |
Equipment and workflow claims may be enforceable |
| Individualized dosimetry |
Moderate |
Claims depend on technical implementation |
| Redifferentiation combinations |
Moderate to strong |
New drug combinations and methods may remain protected |
| Supply-chain and manufacturing know-how |
Moderate |
Trade secrets and operational execution matter |
A freedom-to-operate review should focus on formulation claims, combination patents, dosimetry software, packaging, and process claims. A search limited to the chemical name will understate the relevant risk.
Which companies supply sodium iodide I-131?
Supply is distributed among radiopharmaceutical manufacturers, reactor-linked producers, nuclear pharmacies, and hospital-based facilities. Market participation varies by country and product presentation.
Known industry participants in radioiodine and broader therapeutic radiopharmaceutical supply include:
- Curium.
- Jubilant Radiopharma.
- Cardinal Health Nuclear & Precision Health Solutions.
- NorthStar Medical Radioisotopes.
- Eckert & Ziegler.
- NTP Radioisotopes.
- IRE.
- Global nuclear-pharmacy networks.
- Regional hospital and university nuclear-medicine pharmacies.
The exact supplier set depends on national licensing, available dosage forms, distribution radius, and reactor or accelerator access. I-131 supply is less vulnerable to the molybdenum-99 supply-chain model because iodine-131 can be produced through uranium fission and neutron irradiation routes, but production interruptions can still create regional shortages.
What manufacturing and IP barriers affect sodium iodide I-131?
The principal barriers are operational rather than patent-based.
Radioisotope production
Iodine-131 production requires specialized nuclear infrastructure, irradiation capability, radiochemical separation, containment, and validated release testing. The product cannot be stockpiled in the same way as a conventional tablet because its activity decays continuously.
Short distribution window
An eight-day physical half-life creates commercial pressure at every stage:
- Production must be scheduled against demand.
- Dose calibration must account for decay.
- Transportation must comply with radioactive-material rules.
- Hospitals must coordinate administration dates.
- Cancellations can create unrecoverable inventory loss.
Quality and compliance
Manufacturers must control radionuclidic purity, radiochemical purity, chemical purity, sterility where applicable, activity calibration, packaging, labeling, and release timing. These requirements increase fixed costs even when the underlying drug substance is inexpensive.
Facility requirements
Treatment centers may need shielded rooms, radiation-safety personnel, contamination-control procedures, patient-release protocols, and inpatient capacity for higher administered activities. These constraints reduce the number of potential providers.
How large is the sodium iodide I-131 market?
There is no consistently reported global revenue figure for sodium iodide I-131 as a standalone product. Public market reports usually place it inside broader categories such as therapeutic radiopharmaceuticals, nuclear medicine, or thyroid-cancer treatment.
A practical market model uses treatment volume, administered activity, product price, and distribution geography:
[
\text{Market value} = \text{treated patients} \times \text{activity per patient} \times \text{net price per activity unit}
]
The market has two large demand pools:
- Benign thyroid disease, particularly Graves' disease and toxic nodular disease.
- Differentiated thyroid cancer, including remnant ablation and metastatic treatment.
Demand is relatively stable in benign disease but is more exposed to treatment substitution in thyroid cancer. Guidelines have reduced routine radioiodine use for selected low-risk patients, while improved diagnosis and longer survival support continued use in intermediate-risk and metastatic disease.[3]
Market drivers
- High prevalence of thyroid disease.
- Continued use of radioiodine as a definitive treatment for hyperthyroidism.
- Global incidence of thyroid cancer.
- Growth of nuclear-medicine infrastructure.
- Increased use of outpatient radioiodine treatment.
- Development of therapies that restore radioiodine uptake.
- Demand for individualized dosimetry.
Market constraints
- Surgery and antithyroid drugs for hyperthyroidism.
- Active surveillance for selected low-risk thyroid cancers.
- Radioiodine-refractory tumors.
- Radiation-safety restrictions.
- Limited specialist capacity.
- Short isotope shelf life.
- Supplier concentration in some countries.
- Long-term adverse-effect concerns, including salivary-gland injury and second malignancy risk.
What is the sodium iodide I-131 market projection through 2030?
The most defensible projection is low-single-digit nominal growth, with substantial regional variation.
| Scenario, 2024-2030 |
Implied market direction |
Main assumptions |
| Downside |
Flat to declining |
Lower use in low-risk thyroid cancer; stable or lower benign-disease volume |
| Base case |
Approximately 2% to 4% annual growth |
Stable hyperthyroidism demand, modest cancer-treatment growth, pricing and capacity improvements |
| Upside |
Approximately 5% to 7% annual growth |
Expanded use from redifferentiation combinations, improved access in emerging markets, higher treatment volumes |
Under the base case, the product market should expand more slowly than the broader therapeutic radiopharmaceutical sector. High-growth radioligand products, including PSMA-directed and somatostatin-receptor therapies, have stronger commercial momentum because they address large oncology indications with premium pricing. Sodium iodide I-131 remains a high-volume, lower-price, mature product.
Regional growth prospects differ:
| Region |
Outlook through 2030 |
| United States |
Low growth; mature infrastructure and strong competition |
| Western Europe |
Low growth; guideline-driven utilization and centralized supply |
| Japan and South Korea |
Stable demand with sophisticated thyroid-cancer and nuclear-medicine systems |
| China |
Moderate growth as nuclear-medicine capacity expands |
| India |
Moderate to high volume growth from broader access, offset by infrastructure limits |
| Latin America |
Moderate growth concentrated in major metropolitan centers |
| Middle East and Africa |
Uneven growth; dependent on isotope access and treatment facilities |
Which companies are challenging the sodium iodide I-131 market?
Competition is fragmented rather than organized around a single branded challenger. The main competitive groups are:
- Generic radiopharmaceutical manufacturers.
- Nuclear pharmacies.
- Hospital-based production units.
- Alternative thyroid-cancer treatments.
- Alternative hyperthyroidism treatments.
- Companies developing redifferentiation therapies.
- Developers of targeted radioligand therapies competing for nuclear-medicine capacity.
For differentiated thyroid cancer, competition includes surgery, active surveillance, external-beam radiation, tyrosine-kinase inhibitors, BRAF/MEK-directed therapy, and systemic treatments for radioiodine-refractory disease. For hyperthyroidism, alternatives include methimazole, propylthiouracil in selected settings, thyroidectomy, and iodine-131 itself.
What patent litigation and Paragraph IV risks affect sodium iodide I-131?
There is no widely recognized high-value Paragraph IV litigation campaign centered on sodium iodide I-131 comparable to disputes involving branded tablets, injectable biologics, or complex drug-device products.
The risk profile is more likely to involve:
- Product-specific ANDA or NDA disputes.
- Manufacturing-process claims.
- Capsule or solution formulation claims.
- Labeling and method-of-use patents.
- Combination patents involving redifferentiation agents.
- Regulatory disputes over radioactive-material production and distribution.
- Contract and supply disputes between nuclear pharmacies and health systems.
A generic entrant would generally face a low composition-of-matter barrier. The commercial challenge would be proving reliable supply and obtaining institutional adoption rather than overcoming a dominant patent family.
How does sodium iodide I-131 compare with newer radiopharmaceuticals?
| Attribute |
Sodium iodide I-131 |
Newer therapeutic radiopharmaceuticals |
| Clinical maturity |
Decades of use |
Often recently approved or in trials |
| Pricing |
Generally low to moderate |
Often high |
| Patent protection |
Limited |
Frequently significant |
| Targeting mechanism |
Physiologic thyroid uptake |
Molecular tumor-targeting ligand |
| Manufacturing complexity |
High operational complexity |
Often very high |
| Patient population |
Thyroid disease and iodine-avid cancer |
Selected biomarker-defined tumors |
| Supply risk |
Radioisotope and logistics |
Isotope, ligand, manufacturing, and capacity |
| Market growth |
Low-single-digit potential |
Higher, but dependent on approvals and capacity |
I-131 remains difficult to displace in iodine-avid thyroid disease because it is directly aligned with the biology of the thyroid and some differentiated thyroid tumors. Newer radioligands do not replace it across those indications.
What are the main generic launch scenarios?
Scenario 1: Regional low-price entry
A new supplier enters one national market with capsules or solution. The entrant competes on contract pricing and supply reliability. Price erosion is limited because radioactive logistics and fixed manufacturing costs constrain discounting.
Scenario 2: Nuclear-pharmacy expansion
A large radiopharmacy network adds I-131 to its existing distribution system. This is more commercially plausible than a standalone pharmaceutical launch because the network already has radioactive-material licenses, personnel, transport systems, and hospital relationships.
Scenario 3: Hospital-based production
A major academic center develops or expands internal radiopharmaceutical capability. This reduces external purchasing but does not necessarily create a scalable commercial competitor.
Scenario 4: Combination-driven demand expansion
A redifferentiation therapy restores iodine uptake in selected refractory tumors. I-131 demand increases, but much of the incremental value accrues to the combination drug and diagnostic selection platform.
What is the investment outlook for sodium iodide I-131?
Sodium iodide I-131 is a defensive, infrastructure-dependent radiopharmaceutical rather than a high-growth patent asset. Attractive investment characteristics include recurring clinical demand, established guidelines, low risk of biological obsolescence in iodine-avid disease, and the ability to leverage existing nuclear-pharmacy infrastructure.
Key risks include low product differentiation, reimbursement pressure, radioactive-isotope supply interruptions, regulatory compliance costs, and the shift away from routine radioiodine ablation in selected low-risk thyroid cancers.
Revenue exposure is usually more meaningful for diversified radiopharmaceutical suppliers than for I-131 as an isolated product. The strongest commercial positions are likely to belong to companies that control production, distribution, nuclear pharmacy services, and hospital contracts simultaneously.
Key Takeaways
- Sodium iodide I-131 is an established FDA-approved therapy for hyperthyroidism and iodine-avid differentiated thyroid cancer.
- Conventional clinical development is limited; research focuses on dosimetry, patient selection, preparation, and combination therapy.
- The active ingredient has little meaningful patent exclusivity.
- Formulation, manufacturing, dosimetry, and combination patents create the main IP issues.
- Generic entry risk is high in principle, but radioactive-material licensing and supply-chain execution limit practical entry.
- The standalone market is mature and likely to grow at a low-single-digit rate through 2030.
- Redifferentiation therapies could expand demand in radioiodine-refractory thyroid cancer.
- New radioligand therapies compete for nuclear-medicine infrastructure but do not broadly replace I-131 in thyroid disease.
- Commercial value rests more on reliable isotope supply and distribution than on patent ownership.
FAQs
Is sodium iodide I-131 still widely used for Graves' disease?
Yes. It remains an established definitive treatment option, although use varies by patient preference, pregnancy status, ophthalmopathy risk, local practice, and availability of surgery or antithyroid drugs.
Can sodium iodide I-131 be substituted by iodine-123?
No. Iodine-123 is primarily a diagnostic isotope with different radiation characteristics and is not a direct therapeutic substitute for I-131.
Does sodium iodide I-131 require a biosimilar pathway?
No. It is a radioactive small-molecule drug, not a biologic. Biosimilar regulation does not apply.
Is I-131 treatment protected by method-of-use patents?
The basic use of I-131 for thyroid disease is longstanding. Newer combinations, patient-selection methods, dosimetry systems, and redifferentiation regimens may carry active method-of-use or technology patents.
What is the biggest commercial risk for an I-131 supplier?
The largest risk is operational interruption, including isotope-production failure, transportation delays, facility shutdowns, calibration problems, or inability to deliver activity within the treatment window.
References
-
U.S. Food and Drug Administration. (n.d.). Sodium iodide I-131 capsules and oral solution: Prescribing information. FDA Drugs@FDA.
-
National Library of Medicine. (n.d.). ClinicalTrials.gov search results for sodium iodide I-131, radioiodine, differentiated thyroid cancer, and hyperthyroidism. ClinicalTrials.gov.
-
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., Schuff, K. G., Sherman, S. I., Sosa, J. A., Steward, D. L., Tuttle, R. M., & Wartofsky, L. (2016). 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 26(1), 1-133.
-
International Atomic Energy Agency. (2022). Nuclear medicine resources manual. IAEA.
-
National Cancer Institute. (n.d.). Thyroid cancer treatment. National Institutes of Health.
-
International Agency for Research on Cancer. (2024). Global Cancer Observatory: Thyroid cancer fact sheet. World Health Organization.
